T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement.

MLA

Heerma van Voss, Marise R., et al. “T-Cell Redirecting Bispecific Antibody Treatment in Multiple Myeloma: Current Knowledge and Future Strategies for Sustained T-Cell Engagement.” Expert Opinion on Biological Therapy, vol. 24, no. 9, Sept. 2024, pp. 889–901. EBSCOhost, https://doi.org/10.1080/14712598.2024.2397436.

APA

Heerma van Voss, M. R., Molenaar, R. J., Korst, C. L. B. M., Bartelink, I. H., Baglio, S. R., Kruyswijk, S., de Ruijter, M., Zweegman, S., Kuipers, M. T., & van de Donk, N. W. C. J. (2024). T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement. Expert Opinion on Biological Therapy, 24(9), 889–901. https://doi.org/10.1080/14712598.2024.2397436

Chicago

Heerma van Voss, Marise R., Remco J. Molenaar, Charlotte L. B. M. Korst, Imke H. Bartelink, Serena R. Baglio, Sandy Kruyswijk, Maaike de Ruijter, Sonja Zweegman, Maria T. Kuipers, and Niels W. C. J. van de Donk. 2024. “T-Cell Redirecting Bispecific Antibody Treatment in Multiple Myeloma: Current Knowledge and Future Strategies for Sustained T-Cell Engagement.” Expert Opinion on Biological Therapy 24 (9): 889–901. doi:10.1080/14712598.2024.2397436.